Showing results (211-220 of 261) with videos related to
Sort By:
Pageof 27
ACS Nano|December 26, 2017
Bioinspired Silicification Reveals Structural Detail in Self-Assembled Peptide CagesJohanna M Galloway, Laura Senior, Jordan M Fletcher, et al.Clinical Medicine (London, England)|April 1, 2015
Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathwaysPetros Perros, Colin M Dayan, A Jane Dickinson, et al.Brain Communications|June 6, 2022
Coupling cognitive and brainstem dysfunction in multiple sclerosis-related chronic neuropathic limb painPeter Foley, Yazhuo Kong, Ramune Dirvanskiene, et al.Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.Marine Drugs|March 6, 2021
A New <i>Micromonospora</i> Strain with Antibiotic Activity Isolated from the Microbiome of a Mid-Atlantic Deep-Sea SpongeCatherine R Back, Henry L Stennett, Sam E Williams, et al.Marine Drugs|April 27, 2023
Correction: Back et al. A New <i>Micromonospora</i> Strain with Antibiotic Activity Isolated from the Microbiome of a Mid-Atlantic Deep-Sea Sponge. <i>Mar. Drugs</i> 2021, <i>19</i>, 105Catherine R Back, Henry L Stennett, Sam E Williams, et al.Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.Pageof 27